The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Growth In Market Value Is Anticipated For The Genomic Biomarker Market Between 2026 And 2030?
The genomic biomarker market size has experienced substantial growth in recent times. This market is set to expand from $9.9 billion in 2025 to $11.67 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.8%. The historical expansion in this sector can be attributed to factors such as increased investment in genomic research, a proliferation of oncology-focused biomarker studies, the rising availability of next-generation sequencing technologies, enhanced collaboration between diagnostics and pharmaceutical companies, and the early embrace of personalized medicine approaches.
The genomic biomarker market is anticipated to experience substantial expansion in the coming years. Its valuation is set to reach $22.23 billion by 2030, driven by a compound annual growth rate (CAGR) of 17.5%. This anticipated growth during the forecast timeframe is primarily driven by factors such as the heightened demand for personalized medicine treatments, the expanding application of biomarkers in pharmaceutical development, wider integration of companion diagnostics, an intensified emphasis on discovering diseases at earlier stages, and increased regulatory backing for biomarker-driven approvals. Key developments expected throughout this period encompass the wider acceptance of predictive genomic biomarkers, an uptick in pharmacogenomic testing, greater incorporation of genomic data into clinical diagnosis and treatment plans, the spread of biomarker-reliant oncology diagnostics, and a sharpened emphasis on benchmarks for clinical validation.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20557&type=smp
Which Major Factors Are Contributing To The Development Of The Genomic Biomarker Market?
The increasing incidence of chronic diseases is projected to drive the growth of the genomic biomarker market moving forward. Chronic diseases are long-term health conditions that persist and often advance slowly. The rising prevalence of these conditions is attributable to aging populations and an increase in lifestyle-related factors such as obesity and diabetes. Genomic biomarkers enable the early detection and personalized prevention strategies for chronic diseases by identifying genetic predispositions and customizing interventions. This proactive approach helps decrease prevalence by targeting individuals at risk before the onset of the disease. For example, in September 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that 41 million deaths occur worldwide each year, representing 74% of all fatalities attributed to chronic diseases. This figure includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Thus, the growing prevalence of chronic diseases serves as a key driver for the genomic biomarker market.
Which Segment Divisions Form The Structure Of The Genomic Biomarker Market?
The genomic biomarker market covered in this report is segmented –
1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users
Subsegments:
1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction
2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis
What Trends Are Affecting The Genomic Biomarker Market Dynamics?
Leading companies in the genomic biomarker market are concentrating on developing sophisticated products, such as advanced liquid biopsy assays, to facilitate comprehensive genomic profiling of solid tumors. A liquid biopsy assay serves as a diagnostic test that examines genetic material, typically circulating tumor DNA (ctDNA), from a blood sample to detect and monitor cancer. The identification of genomic biomarkers can reveal information about specific mutations, gene expression profiles, or other genetic alterations associated with cancer. For instance, in November 2023, Illumina Inc., a US-based biotechnology company, introduced an advanced liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), for comprehensive genomic profiling of solid tumors. This assay offers enhanced analytical sensitivity, detecting low-frequency variants with just 20 ng of cell-free DNA, a decrease from 30 ng. It delivers results in under four days, considerably accelerating genomic profiling compared to traditional methods. The streamlined workflow and forthcoming automation features are designed to simplify lab integration and boost efficiency.
Who Are The Major Companies Operating In The Genomic Biomarker Market?
Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.
Access The Complete Genomic Biomarker Market Report:
https://www.thebusinessresearchcompany.com/report/genomic-biomarker-global-market-report
What Is The Largest Regional Market In The Genomic Biomarker Market?
North America was the largest region in the genomic biomarker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Genomic Biomarker Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=20557&type=smp
Browse Through More Reports Similar to the Global Genomic Biomarker Market 2026, By The Business Research Company
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Renal Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
Cancer Biomarker Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model